TW202409016A - 表皮生長因子受體抑制劑之鹽及晶體形式 - Google Patents

表皮生長因子受體抑制劑之鹽及晶體形式 Download PDF

Info

Publication number
TW202409016A
TW202409016A TW112116649A TW112116649A TW202409016A TW 202409016 A TW202409016 A TW 202409016A TW 112116649 A TW112116649 A TW 112116649A TW 112116649 A TW112116649 A TW 112116649A TW 202409016 A TW202409016 A TW 202409016A
Authority
TW
Taiwan
Prior art keywords
egfr
ray powder
powder diffraction
crystalline
salt
Prior art date
Application number
TW112116649A
Other languages
English (en)
Chinese (zh)
Inventor
艾瑞克 格魯夫
善明 匡
安嘉理 潘迪
哈許 沙
謝天
Original Assignee
美商纜圖藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商纜圖藥品公司 filed Critical 美商纜圖藥品公司
Publication of TW202409016A publication Critical patent/TW202409016A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW112116649A 2022-05-04 2023-05-04 表皮生長因子受體抑制劑之鹽及晶體形式 TW202409016A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
US63/338,371 2022-05-04

Publications (1)

Publication Number Publication Date
TW202409016A true TW202409016A (zh) 2024-03-01

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112116649A TW202409016A (zh) 2022-05-04 2023-05-04 表皮生長因子受體抑制劑之鹽及晶體形式

Country Status (12)

Country Link
US (1) US20250282761A1 (enExample)
EP (1) EP4519254A1 (enExample)
JP (1) JP2025517634A (enExample)
KR (1) KR20250012078A (enExample)
CN (1) CN119923392A (enExample)
AU (1) AU2023265064A1 (enExample)
CA (1) CA3251624A1 (enExample)
IL (1) IL316663A (enExample)
MX (1) MX2024013485A (enExample)
TW (1) TW202409016A (enExample)
UY (1) UY40256A (enExample)
WO (1) WO2023215431A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097270A1 (en) * 2022-11-01 2024-05-10 Blueprint Medicines Corporation Egfr inhibitors for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
IL302457A (en) * 2020-10-30 2023-06-01 Blueprint Medicines Corp Pyrimidine compounds, preparations and their medical applications
CA3196857A1 (en) * 2020-10-30 2022-05-05 Gurulingappa Hallur Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
AU2023265064A1 (en) 2024-11-14
US20250282761A1 (en) 2025-09-11
MX2024013485A (es) 2024-12-06
IL316663A (en) 2024-12-01
WO2023215431A1 (en) 2023-11-09
EP4519254A1 (en) 2025-03-12
JP2025517634A (ja) 2025-06-10
CN119923392A (zh) 2025-05-02
KR20250012078A (ko) 2025-01-23
CA3251624A1 (en) 2023-11-09
UY40256A (es) 2023-11-15

Similar Documents

Publication Publication Date Title
JP5562033B2 (ja) ２−メチル−２−［４−（３−メチル−２−オキソ−８−キノリン−３−イル−２，３−ジヒドロ−イミダゾ［４，５−ｃ］キノリン−１−イル）−フェニル］−プロピオニトリルの塩および結晶形態
TWI845657B (zh) (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法
US9630952B2 (en) Crystalline forms of afatinib di-maleate
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
CN115461341A (zh) 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的晶型
WO2019042444A1 (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
CN102510855A (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
CN102918029B (zh) 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
JP7054528B2 (ja) プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
JP2018537486A (ja) キノロン類似体及びその塩の結晶形
CN112119074A (zh) Egfr抑制剂
WO2019196938A1 (zh) 喹唑啉类化合物作为egfr三突变抑制剂及其应用
KR20200032152A (ko) N-페닐-2-아미노피리미딘 화합물의 결정형과 염형, 및 이의 제조 방법
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
TW202328084A (zh) 聯芳基ｙａｐ／ｔａｚ—ｔｅａｄ蛋白—蛋白相互作用抑制劑之結晶形式
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
WO2019154133A1 (zh) 二噁烷并喹啉类化合物及其制备方法与应用
JP7618575B2 (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
JP2023505254A (ja) ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドを製造するための方法
WO2019170086A1 (zh) 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用
CN103626761A (zh) 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
TW202527935A (zh) 吲唑巨環多晶型物